Northwell Health

Running trials

• Not yet recruiting

  Advancing Ethical Goals In Society Trial

  NCT07824245· Tufts Medical Center· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

  NCT07625332· Phase 2/3· Northwell Health· Source

• Recruiting

  Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  NCT07804186· Phase 3· IDEAYA Biosciences· Source

• Enrolling by invitation

  Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study

  NCT07676097· AngioInsight· Source

• Recruiting

  A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

  NCT07330258· Bayer· Source

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Not yet recruiting

  The Canopy Cancer Collective Clinical Registry Protocol

  NCT07605702· Canopy Cancer Collective, LLC· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

  NCT05148156· Northwell Health· Source

• Recruiting

  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  NCT07225621· Phase 2· Alpheus Medical, Inc.· Source

• Recruiting

  Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Pilot RCT

  NCT07254065· Northwell Health· Source

• Active, not recruiting

  SPI-1005 for the Treatment of Meniere's Disease (Open Label)

  NCT06859788· Phase 3· Sound Pharmaceuticals, Incorporated· Source

• Recruiting

  BoxX-NoAF Clinical Trial

  NCT06989775· AtriCure, Inc.· Source

• Recruiting

  A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

  NCT06570798· Phase 2· Amgen· Source

• Recruiting

  Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

  NCT06972056· Phase 4· Mayo Clinic· Source

• Recruiting

  Study With Phage for CF Subjects With Pseudomonas Lung Infection

  NCT06998043· Phase 2· BiomX Ltd· Source

• Recruiting

  Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young Adults With Cystic Fibrosis (CF)

  NCT07930884· Northwell Health· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Recruiting

  Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

  NCT05730283· Phase 2· Kevin Winthrop· Source

• Recruiting

  A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT06533644· Phase 2· Syncromune, Inc.· Source

• Recruiting

  A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  NCT06876649· Phase 4· Eli Lilly and Company· Source

• Recruiting

  A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  NCT06876662· Phase 4· Eli Lilly and Company· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Medtronic Cardiovascular· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT06388421· United Therapeutics· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Recruiting

  DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

  NCT06504381· Phase 1/2· University of California, San Francisco· Source

• Active, not recruiting

  Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

  NCT06498960· CereVasc Inc· Source

• Recruiting

  Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

  NCT06486454· HistoSonics, Inc.· Source

• Active, not recruiting

  SIMPLAAFY Clinical Trial

  NCT06521463· Boston Scientific Corporation· Source

• Active, not recruiting

  ADVENT Post Approval Study

  NCT06431815· Boston Scientific Corporation· Source

• Recruiting

  A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  NCT06413680· Phase 1/2· Regeneron Pharmaceuticals· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

  NCT06172127· Phase 2· MedSIR· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source

• Recruiting

  Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

  NCT06056271· Volta Medical· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Incremental Hemodialysis: The TwoPlus Trial

  NCT05828823· Wake Forest University Health Sciences· Source

• Recruiting

  Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

  NCT06190717· Sonavex, Inc.· Source

• Active, not recruiting

  Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

  NCT06151574· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Phase 4· Amgen· Source

• Active, not recruiting

  GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

  NCT05818150· Merit Medical Systems, Inc.· Source

• Recruiting

  CONVIVO Endomicroscopy

  NCT06087393· Northwell Health· Source

Showing 50 of 104.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation3 recruiting
• Chronic kidney disease3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Cystic fibrosis2 recruiting
• Epilepsy2 recruiting
• Glioblastoma2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Obesity2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• Alzheimer disease1 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic stenosis1 recruiting
• Bronchiectasis1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Fabry disease1 recruiting
• Gaucher disease1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Migraine1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoarthritis1 recruiting
• Pancreatic cancer1 recruiting
• Pompe disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

  NCT06828666· Phase 1/2· Britecyte· Source

• Withdrawn

  SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

  NCT06719531· Medtronic MiniMed, Inc.· Source

• Terminated

  Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

  NCT06543446· University of Rochester· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Completed

  ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

  NCT06526546· Boston Scientific Corporation· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Terminated

  KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

  NCT06400303· Phase 1/2· Kyverna Therapeutics· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Orchestra BioMed, Inc· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

  NCT06000410· Phase 3· Organogenesis· Source

• Completed

  Myositis Interstitial Lung Disease Nintedanib Trial

  NCT05799755· Phase 4· Rohit Aggarwal, MD· Source

• Completed

  Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

  NCT05641896· Phase 2· SOFIE· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Completed

  Microfragmented Adipose Tissue Compared to Corticosteroid Injection for the Treatment of Knee Osteoarthritis

  NCT05660772· Phase 3· Lipogems International spa· Source

• Completed

  Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

  NCT05626634· Phase 2· Longboard Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

  NCT05453578· Phase 1/2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Leap Therapeutics, Inc.· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Nuwellis, Inc.· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Completed

  Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

  NCT05364021· Phase 1/2· Longboard Pharmaceuticals· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Recruiting

  A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

  NCT05150691· Phase 1/2· DualityBio Inc.· Source

• Completed

  Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System

  NCT05120193· Medtronic Cardiac Ablation Solutions· Source

• Completed

  A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

  NCT04853017· Phase 1· Elicio Therapeutics· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Nucleix Ltd.· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Bayer· Source

• Completed

  Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

  NCT03961945· Mayo Clinic· Source

• Completed

  Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

  NCT04923880· Massachusetts General Hospital· Source

• Completed

  Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

  NCT04873934· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source

• Completed

  DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

  NCT04825834· Delfi Diagnostics Inc.· Source

• Completed

  Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

  NCT04702451· Volta Medical· Source

• Completed

  Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

  NCT03926520· Brent Forester· Source

• Completed

  Evaluation of AMG 714 for Vitiligo

  NCT04338581· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Pancreatic Adenocarcinoma Signature Stratification for Treatment

  NCT04469556· Phase 2· University Health Network, Toronto· Source

• Terminated

  A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

  NCT04572243· Phase 3· Eisai Inc.· Source

• Completed

  Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

  NCT04456673· Phase 3· Sanofi· Source

• Terminated

  A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

  NCT04487405· Aspira Women's Health· Source

• Completed

  Human Epilepsy Project 3

  NCT05374928· NYU Langone Health· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Amicus Therapeutics· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· PrECOG, LLC.· Source

• Completed

  Trial of Parkinson's And Zoledronic Acid

  NCT03924414· Phase 4· California Pacific Medical Center Research Institute· Source

• Completed

  Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

  NCT04075825· Phase 3· Takeda· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

  NCT03795298· Boston Scientific Corporation· Source

Showing 50 of 65.

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure99 works · 3 trials
• Schizophrenia78 works · 1 trial
• Atrial fibrillation68 works · 13 trials
• Pancreatic cancer39 works · 10 trials
• Coronary artery disease39 works · 8 trials
• Melanoma38 works · 4 trials
• Lupus (SLE)34 works · 4 trials
• Hidradenitis suppurativa27 works · 1 trial
• Bipolar disorder20 works · 0 trials
• Cystic fibrosis19 works · 4 trials
• Meningioma14 works · 0 trials
• Ventricular tachycardia13 works · 1 trial
• Endometrial cancer13 works · 3 trials
• Sickle cell disease12 works · 1 trial
• Neuroendocrine tumours11 works · 0 trials
• Hypertrophic cardiomyopathy11 works · 0 trials
• Aortic stenosis11 works · 3 trials
• Myocarditis9 works · 0 trials
• Hypothyroidism9 works · 0 trials
• Bronchiectasis8 works · 3 trials
• Vitiligo8 works · 1 trial
• Hydrocephalus7 works · 1 trial
• Brain aneurysm6 works · 1 trial
• Alopecia areata6 works · 0 trials
• Graves' disease and hyperthyroidism5 works · 0 trials
• IgA nephropathy4 works · 0 trials
• Dermatomyositis and polymyositis (myositis)4 works · 3 trials
• Lyme disease4 works · 0 trials
• Trigeminal neuralgia4 works · 0 trials
• Aplastic anaemia3 works · 0 trials